News

Dr Y. Ralph Chu explains how the ongoing development of increasingly customized IOLs is providing refractive-cataract surgery patients individualized options.

Bilateral implantation of the Acri.LISA 366D diffractive bifocal IOL is effective in ametropic and presbyopic eyes, according to findings published in the European Journal of Ophthalmology

Dr Mark Wevill discusses the changes occuring in the field of femtosecond lasers and the advantages this technology has enabled.

Dr Liliana Werner highlights the results of her research with the Sulcofex, revealing why this is an attractive option for supplementary IOL implatation.

There are still many challenges facing clinicians in the regeneration of the optic nerve. Dr M. Francesca Cordeiro reveals encouraging research results to help overcome these barriers.

A round up of new products

A retrospective study of cataract patients who underwent phacoemulsification with implantation of the Toric Microsil 6116 TU IOL is described.

Examining the potential of various strategies in the restoration of vision after brain damage previously thought to be permanent

phosphodiesterase-5 inhibitor, sildenafil citrate, increases chorodial thickness ? an associated risk factor for central serous chorioretinopathy

The Lenstar LS 900 and applanation ultrasound can be used interchangeably for biometric measurement in cataract patients

Oertli has welcomed several new employees to their recently improved Marketing and Sales department

A recent LASIK panel symposium has revealed the progresses and plans for the LASIK Quality of Life Collaboration Project.

Anterior segment optical coherence tomography (AS-OCT) is a useful imaging tool for flap thickness measurement after femtosecond-assisted LASIK

The visual acuity (VA) in diabetic retinopathy is associated with the retinal oedema in the parafovea and the pathomorphology and photoreceptor status at the fovea

Bottle rocket injuries can cause serious ocular injury or permanent loss of vision in children and adolescents

Flap creation for bilateral LASIK is best performed using an IntraLase, VisuMax or Femto LDV, rather than a microkeratome.

An increase in HIV-related syphilis has been linked with a rise in ophthalmic manifestations

Sodium hyaluronate (SH) and carboxymethylcellulose (CMC) are safe and effective in treating mild to moderate dry eye disease

Virectomy with 360º retinectomy can be beneficial for the treatment of complex retinal detachments

The presence of cataracts could influence optical coherence tomography (OCT) signal strength (SS) and peripapillary retinal nerve fibre layer (RNFL) thickness measurements

A new training centre has been built in Bangalore, India, for ophthalmologists and related medical staff

The most frequent ocular complaints in patients suffering from Parkinson's disease (PD) are dry eye syndrome and glaucoma.

CORNEA_PROTECT® (2% HPMC) guarantees protection and moisturization of the corneal surface during surgical procedures for up to 20 min. Also applications as a contact agent are possible.

Hydroxychloroquine and chloroquine are strongly associated with retinal toxicity in patients with a lean body weight,

A treatment for dry eye syndrome is to undergo a phase III randomized, placebo-controlled, multicentre study this year following a final licensing agreement with Celtic Therapeutics.

An investigation, published in Inorganic Chemistry, has revealed that the reaction of pirenoxine (PRX) with selenite or calcium ions could be adapted as an anti-cataract agent.

Combined use of intracorneal ring segments (KERARINGS) and corneal collagen cross-linking (CXL) in a single session is more effective than performing the procedure in two sessions

Androgen deprivation therapy (ADT) used for prostate cancer treatment could contribute towards the development of cataracts.

Bausch + Lomb has introduced a free iPhone application that will test a patient's visual acuity and colour vision, enable them to learn more about cataracts and Crystalens and find a suitable surgeon.

Novartis has received the eagerly anticipated approval from the European Commission for Lucentis (ranibizumab) to treat visual impairment due to diabetic macular oedema (DME).